Abstract
Histopathologic evaluation is essential for categorizing and studying neuromuscular disorders. However, experienced specialists and pathologists are limited, especially in underserved areas. Although new technologies, such as artificial intelligence, are expected to improve medical reach, their use in rare diseases is challenging because of the limited availability of training datasets. To address this knowledge gap, we developed an algorithm based on deep convolutional neural networks that used data from microscopic images of hematoxylin-and-eosin-stained pathology slides. Our algorithm differentiated idiopathic inflammatory myopathies (mostly treatable) from hereditary muscle diseases (mostly non-treatable) and achieved better sensitivity and specificity than real physicians’ diagnoses. Furthermore, it successfully and accurately classified four subtypes of the abovementioned muscular conditions. These results suggest that our algorithm can be safely used in a clinical setting. We established the similarity between the algorithm’s and physicians’ predictions using visualization technology, and clarified the validity of the predictions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Japan Agency for Medical Research and Development (AMED) under grant number JP18ek0109348.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee at National Center of Neurology and Psychiatry
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Detailed data will be available upon request.
